MBX Biosciences Quarterly Income Statement
NASDAQ: MBXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
53.24-0.01 (-0.02%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
MBX Biosciences revenue and earnings
MBX Biosciences reported a net loss of $37.1 million, compared with a loss of $19.4 million a year earlier. Diluted earnings per share came in at -$0.78.
Summary generated from market data by MetaCap's automated system. Methodology
MBX Biosciences income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Expenses | 40.93M | 27.27M | 25.80M | 23.93M | 21.80M | 26.53M | 18.61M | 19.61M | 16.66M | 13.31M | 9.99M | 10.95M |
| Research & Development | 30.98M | 18.47M | 19.76M | 19.27M | 17.72M | 22.41M | 15.22M | 16.75M | 14.40M | 11.05M | 7.73M | 9.07M |
| Operating Income | -40.93M | -27.27M | -25.80M | -23.93M | -21.80M | -26.53M | -18.61M | -19.61M | -16.66M | -13.31M | -9.99M | -10.95M |
| Net Income | -37.09M | -23.52M | -22.09M | -21.62M | -19.41M | -23.88M | -15.59M | -18.14M | -15.86M | -12.34M | -8.84M | -10.16M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -0.78 | -0.50 | -0.46 | -0.63 | -0.58 | -0.71 | 19.84 | -2.78 | -12.62 | -10.26 | — | -9.40 |
| EPS (Diluted) | -0.78 | -0.50 | -0.46 | -0.63 | -0.58 | -0.71 | 19.84 | -2.78 | -12.62 | -10.26 | — | -9.40 |
| Shares Outstanding (Basic) | 47.70M | 46.58M | — | 34.20M | 33.45M | 33.41M | — | 6.52M | 1.26M | 1.20M | — | 1.08M |
| Shares Outstanding (Diluted) | 47.70M | 46.58M | — | 34.20M | 33.45M | 33.41M | — | 6.52M | 1.26M | 1.20M | — | 1.08M |
| EBITDA | -40.83M | -27.20M | -25.73M | -23.83M | -21.70M | -26.45M | -18.55M | -19.51M | -16.56M | -13.27M | -9.95M | -10.85M |
This table shows 12 quarterly periods of MBX Biosciences's income statement, from Q2 2026 back to Q3 2023, across 9 line items including operating expenses, research & development, operating income. Values in USD; B = billions, M = millions. Fiscal periods follow MBX's reporting calendar. What is a income statement?